Cyclosporin A for the treatment of graft-versus-host disease in man.
Cyclosporin A was given to five patients with acute leukaemia in whom graft-versus-host disease (G.V.H.D.) had developed after bone-marrow transplantation from sibling donors. In all instances the acute erythematous skin reaction of G.V.H.D. resolved within two days, but four of the five patients died. Cyclosporin A in high doses produced anorexia, nausea, and a reversible rise in blood-urea. The four patients who died all had liver damage, but the histological changes varied. Cyclosporin A modifies the acute skin reaction of G.V.H.D. In the management of liver and gut G.V.H.D., and in prophylaxis of G.V.H.D., its role needs to be determined.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D004341:Drug Evaluation; D005260:Female; D005656:Fungal Proteins / Q000627:therapeutic use*; D006087:Graft vs Host Reaction / Q000187:drug effects*; D006501:Hepatic Encephalopathy / Q000139:chemically induced; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007273:Injections, Intramuscular; D007948:Leukemia, Monocytic, Acute / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D008111:Liver Function Tests; D008297:Male; D010455:Peptides / Q000008:administration & dosage; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000188:drug therapy*; D014185:Transplantation, Isogeneic
D005656:Fungal Proteins; D007166:Immunosuppressive Agents; D010455:Peptides; D010456:Peptides, Cyclic